Covid-19 manufacturing roundup: Moderna eyes Nexus' Wisconsin plant for vaccine boost; Catalent wraps up plant project
After an immediate demand for Covid-19 vaccines has opened back up following the CDC’s pause on J&J’s jab, Moderna is looking to boost production of its own.
The company met with Nexus Pharmaceuticals to talk about making the shot at the company’s Pleasant Prairie, WI plant, Reuters reported.
President Joe Biden has said that there will be enough vaccines for all US adults by May. This move could help the country reach that milestone. According to Reuters, White House officials have facilitated discussions between Nexus, Moderna and J&J.
Right now, Nexus is not manufacturing Covid-19 vaccines. Its new Wisconsin facility, roughly a 35-minute drive south of Milwaukee and just southwest of Kenosha was announced in 2019 and saw an investment of roughly $250 million.
Tuesday, a pause on distribution of the J&J vaccine was called for after 6 blood clots in women under the age of 50 were reported. The pause should only last a few weeks at the very most, NIH Director Anthony Fauci said, and is certainly not a cancellation.
“I doubt very seriously if we’re talking about weeks to months,” he told CNN on Wednesday.
Catalent wraps Wisconsin plant project in push to double Moderna contract
New Jersey CDMO Catalent has ramped up its production as of late to keep up with the demand of the Covid-19 vaccine. Last week, the company expanded on a deal with Moderna to help try to churn out twice the amount of finished vials by summertime.
Tuesday, the company announced that it has completed the expansion of its Madison, WI manufacturing facility. Two new suites are up and running, and so has the work on customer programs.
Each suite features two 2,000-liter single-use bioreactors. The investment was first announced in January 2019.